Built on the principles of speed, scale and equitable access, CEPI is supporting the research and development of a diverse portfolio of vaccine candidates based on a range of vaccine approaches.
CEPI has made investments in 21 vaccine candidates against its priority pathogens (Lassa, MERS, Rift Valley Fever, Nipah, Chikungunya and Ebola), 14 COVID-19 vaccines, 13 broadly protective coronavirus vaccines, and an array of enabling science projects. The organization has also invested in the development of rapid response platforms to develop vaccines against Disease X (the threat of an unknown virus).
CEPI moved quickly and urgently to accelerate vaccine development in response to the COVID-19 crisis. We announced our first vaccine partnerships on 23 January 2020 when there were just 581 confirmed cases of COVID-19 globally, and swiftly built a large and diverse portfolio of COVID-19 vaccine candidates to maximise our chances of success. Four of these (Oxford/AZ, Moderna, Novavax, SK bioscience) have been granted emergency use listing by the World Health Organization (WHO) and are now preventing disease and death around the world. A further three have been approved for domestic use.
CEPI is also the leading global funder of R&D into broadly protective coronavirus vaccines as part of its plan to minimise the risk of future epidemic and pandemic threats.